6
Participants
Start Date
October 19, 2023
Primary Completion Date
May 31, 2024
Study Completion Date
May 31, 2024
Infigratinib
Infigratinib is a selective ATP-competitive inhibitor of fibroblast growth factor receptor (FGFR) 1-3 that inhibits FGFR downstream signaling and proliferation in human cancer cell lines with FGFR genetic alterations, significantly inhibiting the growth of several types of cancers driven by FGFR amplification, fusion and mutation.
Beijing Cancer Center, Beijing
The First Hospital of China Medical University, Shenyang
Jilin Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Zhongshan Hospital Fudan University, Shanghai
Nanjing Drum Tower Hospital, Nanjing
Anhui Provincial Cancer Hospital, Hefei
The Second Hospital of Anhui Medical University, Hefei
Central Hospital Affiliated to Shandong First Medical University, Jinan
Shandong Provincial Cancer Hosptial, Jinan
The Affiliated Hospital of Qingdao University, Qingdao
Tianjin Medical University Cancer Institute&Hospital, Tianjin
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
Hunan Provincial People's Hospital, Changsha
Tongji Hospital, Tongji Medical College of HUST, Wuhan
Hubei Cancer Hospital, Wuhan
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Guangzhou First People's Hospital, Guangzhou
The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou
Dongguan City People's Hospital, Dongguan
The Second Affiliated Hospital of Guilin Medical University, Guilin
Liuzhou People's Hospital, Liuzhou
West China Hospital of Sichuan University, Chengdu
Sichuan Cancer Hospital, Chengdu
Yunnan Cancer Hospital, Kunming
The Second Hospital Lanzhou University, Lanzhou
The First Affiliated Hospital of Xiamen University, Xiamen
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Affiliated Hospital of Hebei University, Baoding
Shanxi Provincial Cancer Hospital, Taiyuan
Lead Sponsor
LianBio LLC
INDUSTRY